Even if Italy's vote on austerity measures and the replacement for Prime Minister Silvio Berlusconi don't give you chest pains, London -based drug maker AstraZeneca ( AZN) may be a safe place to hide. The maker of heart drug Crestor has seen its shares stay relatively flat since the beginning of 2008 even as the world's been gripped by a global financial crisis not seen since the Great Depression.

The company currently earns more than half of its $33.3 billion in annual sales from the Americas and has seen record operating profits of more than $11 billion since the financial crisis. Compared with rival Germany drugmaker Novartis ( NVS), AstraZeneca has seen shares fall just over 1% this year compared with over 6% for the maker of Diovan. Out of $50.6 billion in annual sales, Novartis generates just 31% of sales from the U.S.

If you liked this article you might like

Democrats Target Megamergers in Populist Political Play

Walmart Is One of 63 Companies Contributing Massively to Aid Harvey Relief

Corporate America Wants a Piece of the Mayweather, McGregor Money Giveaway

With Eyes on Solar Eclipse, Wall Street Stumbles Yet Again